Protagonist Therapeutics (PTGX) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 114.3% versus a loss of 12.8%. Over five years, PTGX leads with a +351.8% price change compared with -7.6% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($10.40 billion vs $9.33 billion), about 1.1 times the size.
On valuation, Dr. Reddy's Laboratories trades at a lower trailing P/E (28.4x vs 140.0x for Protagonist Therapeutics). Dr. Reddy's Laboratories pays a dividend yielding 64.10%, while Protagonist Therapeutics does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTGX | RDY |
|---|---|---|
| Share price | $144.18 | $12.48 |
| Market cap | $9.33B | $10.40B |
| 1-day change | +3.05% | +2.30% |
| YTD return | +60.19% | -13.11% |
| 1-year return | +114.26% | -12.79% |
| 5-year return | +351.76% | -7.59% |
| P/E ratio (TTM) | 139.98 | 28.36 |
| Forward P/E | — | 19.45 |
| EPS (TTM) | $1.03 | $0.44 |
| Dividend yield | 0.00% | 64.10% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $46.02M | $3.81B |
| Revenue growth (YoY) | -89.41% | +13.76% |
| Net income (latest FY) | $-130.15M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | -343.63% | 22.09% |
| Net margin | -282.83% | 17.40% |
| 52-week high | $160.81 | $15.67 |
| 52-week low | $65.75 | $11.36 |
| Distance from 52-week high | -10.34% | -20.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +21.16% | +5.93% |
| Average volume | 623.06K | 2.87M |
| Shares outstanding | 64.71M | 832.99M |
| Employees | 141 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed RDY by 127.1 percentage points over the past year.
- Protagonist Therapeutics trades at a higher earnings multiple (140.0x vs 28.4x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (64.10% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Dr. Reddy's Laboratories grew revenue faster in its latest fiscal year (+13.76% vs -89.41%).
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
PTGX vs RDY FAQ
Which is bigger, Protagonist Therapeutics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $10.40B compared with $9.33B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, PTGX or RDY?
PTGX returned +114.26% over the past 12 months, compared with -12.79% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PTGX or RDY?
RDY has the lower trailing P/E at 28.4, versus 140.0 for PTGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Protagonist Therapeutics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 64.10%, while Protagonist Therapeutics does not currently pay a regular dividend.
Are Protagonist Therapeutics and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.